EMA eCTD Gateway: A Guide to Technical Specifications

By Adrien Laurent, CEO at IntuitionLabs • 1/13/2026 • 35 min read

ema esubmission gateway   ectd submission   regulatory affairs   european medicines agency   as2 protocol

marketing authorization   ectd v4.0   regulatory dossier

Page 1 of 14

EMA eCTD Gateway Specifications

Executive Summary

This comprehensive report examines the **European Medicines Agency (EMA) electronic Common Technical Document (eCTD) Gateway specifications**, covering its history, technical architecture, operational procedures, and strategic implications. The EMA's eSubmission Gateway is a central, secure interface that enables pharmaceutical applicants to submit regulatory dossiers (in eCTD format) over the Internet for marketing authorization applications. Launched in 2012 and fully mandated for human centralised procedure submissions by 2014 (www.ema.europa.eu) (www.ema.europa.eu), the Gateway has since become integral to EMA's digital strategy. Key aspects include the use of **AS2/AS3 protocols for secure file transfer**, mandated file packaging standards (ZIP with no internal encryption) ([1] studylib.net), and an XML-based *delivery file* that conveys dossier metadata (esubmission.ema.europa.eu). Submissions are acknowledged by an automated *Receipt* upon delivery and a formal *Acknowledgment* message after technical validation ([2] studylib.net) ([3] studylib.net). Over time, the system has evolved — for example, a new "Gateway Release II" in January 2026 introduced automated validation confirmations and streamlined uploads (www.ema.europa.eu) — and will continue to adapt to standards like eCTD v4.0, optional from December 2025 (esubmission.ema.europa.eu) (esubmission.ema.europa.eu). This report delves deeply into the Gateway's architecture (Axway Synchrony-based), security model (mutual X.509 certificates, RSA-2048 keys) ([4] studylib.net) ([5] studylib.net), submission requirements (file formats, naming conventions) ([1] studylib.net) ([6] studylib.net), and the user experience (Gateway vs. Web Client; corporate workflows) ([7] studylib.net) (www.pharmaregulatory.in). We provide evidence-based analysis, including regulatory examples and expert commentary, to illuminate how the Gateway streamlines EMA's regulatory lifecycle. Finally, we discuss current challenges and future directions, such as transition to eCTD v4.0 (esubmission.ema.europa.eu), integration of master data (SPOR), and industry impacts of these evolving specifications.

Introduction and Background

The Common Technical Document (CTD) and eCTD

The Common Technical Document (CTD) is a harmonised dossier format established by the **International Council for Harmonisation (ICH)** to standardise marketing authorisation applications for medicinal products. The CTD is organized into five modules covering administrative (Module 1), summaries (Module 2), quality (Module 3), nonclinical (Module 4), and clinical (Module 5) information (esubmission.ema.europa.eu). The *electronic* Common Technical Document (eCTD) transmits the CTD in digital form: PDF documents arranged in the standard module directory structure, indexed by an XML backbone file, with file integrity ensured via checksums (esubmission.ema.europa.eu). Essentially, *"an eCTD is the submission of PDF documents, stored in the eCTD directory structure, accessed through the XML backbone and with the files integrity guaranteed by the MD5 checksum"* (esubmission.ema.europa.eu). The current ICH eCTD Specification version is **3.2.2** (for Modules 2–5）, while the EMA also maintains a regional eCTD Module 1 specification with EU-specific requirements (esubmission.ema.europa.eu).

EMA mandates use of the eCTD for all marketing-authorisation dossiers: *"The eCTD format is mandatory to use for all submission types related to Marketing Authorisation for products within all EU procedures (i.e. Centralised, Decentralised and Mutual Recognition Procedures)"* (esubmission.ema.europa.eu). This requirement reflects a broader digital shift: physical media and paper submission routes have been phased out in favor of secure electronic filing. Indeed, the EMA launched its electronic submission channels to improve efficiency and reduce costs (www.ema.europa.eu) (www.ema.europa.eu). Initially available in pilot form for centralised human applications in 2012 (www.ema.europa.eu),

the eSubmission Gateway is now the primary conduit for EMA filings, with a web-based *Gateway Web Client* as a complementary tool for lower-volume users.

The EMA eSubmission System Architecture

To support eCTD submissions, EMA built an agency-wide electronic submission infrastructure. As of 2026, the key components are:

- **eSubmission Gateway**: A machine-to-machine interface based on the **Axway Synchrony Gateway Interchange** (version 5.x initially) ([8] studylib.net) ([9] studylib.net). It implements the *Electronic Standards for the Transfer of Regulatory Information (ESTRI)* gateway model to provide secure, automated routing of submissions to EMA's internal review systems ([10] studylib.net) (www.ema.europa.eu).

- **eSubmission Web Client**: A browser-based portal (since July 2022 built on the *Axway Syncplicity* platform (esubmission.ema.europa.eu)) intended for small-to-medium companies or occasional filers.It uses HTTPS and a Java applet for uploading packages, requiring minimal client-side setup ([11] studylib.net) (esubmission.ema.europa.eu).

- **XML *Delivery File***: A mandatory metadata manifest (in XML format) that accompanies each submission. It captures identifiers (product number, procedure ID, submission type, sequence number, etc.) that are used by EMA's systems for routing and validation. (Use of this XML delivery file is enforced for all gateway or web-client submissions (esubmission.ema.europa.eu)).)

- **Validation and Review Tools**: Once a package is received, automated technical validation (checking the eCTD structure, file formats, Module 1 data, etc.) is performed by EMA's eCTD Review System (also known as "EURS"), and the dossier is ingested into EMA's case management systems.

- **Notification Mechanisms**: EMA provides immediate digital receipts of transmission and validation results to sponsors. An initial "Receipt" text file acknowledges that the Gateway has obtained the package, and a subsequent XML "Acknowledgment" contains the PASS/FAIL result of technical validation ([2] studylib.net) ([3] studylib.net).

A key remark is that the eSubmission Gateway/Web Client is now *mandatory* for virtually all centralised submissions (www.ema.europa.eu), and strongly recommended (or effectively required) for veterinary submissions as well since April 2014 ([12] studylib.net) ([13] studylib.net). Physical media (e.g. CD/DVD or Eudralink) are still accepted as fallback, but only for first submissions or as a temporary alternative, and must not be used concurrently to avoid duplications (www.ema.europa.eu) ([13] studylib.net). Overall, the EMA's shift to eSubmission centralizes and secures dossier intake, replacing older practices of fax or courier.

Historical and Regulatory Context of the EMA eSubmission Gateway

The EMA's eSubmission network was rolled out in stages as part of a strategic roadmap. Key milestones include:

- **Pilot and Launch (2012)**: Following an internal pilot (Jan–Apr 2012) using a limited set of applicants, the EMA opened the Gateway to *"all applications for centralised marketing authorisations for human medicines"* in mid-2012 (www.ema.europa.eu). At that time, EMA officials observed *"an increase in the speed and efficiency of the application process"* due to electronic transmissions (www.ema.europa.eu). The Gateway used ESTRI protocols (AS2/AS3) and required applicants to set up certificates for mutual authentication (www.ema.europa.eu) ([4] studylib.net).

- **Web Client Launch (2013)**: In January 2013, the EMA introduced a complementary **Web Client** portal for filers with lower technical capabilities or smaller submission volumes (www.ema.europa.eu). This free, web-based front end (modernized to Axway Syncplicity by 2022 (esubmission.ema.europa.eu)) allowed users to upload submissions via an applet, without needing to operate AS2 software. The combination of Gateway and Web Client gave a choice of path (machine vs browser) while moving everyone off physical media.

- **Mandatory eSubmission (2014)**: Effective 1 March 2014, the EMA required that *every* centralised eCTD submission be sent through the Gateway or Web Client (www.ema.europa.eu). For veterinary dossiers, from 1 April 2014 it also became *possible* (and indeed highly recommended) to submit via the Gateway/Web Client ([12] studylib.net) ([13] studylib.net). After these dates, the EMA ceased routine acceptance of paper or Eudralink submissions for those categories. This mandate was underpinned by the EU eSubmission initiative to *"improve efficiency and decrease costs"* (www.ema.europa.eu) for stakeholders and regulators alike.

- **Progressive Extensions (2014–2020s)**: Over time, EMA extended eSubmission to new procedures and formats. For example, periodic safety update reports (PSURs) and active substance master files (ASMFs) were incorporated, and eventually all CAPs (centralised procedure products) could only file eCTD via the Gateway (www.ema.europa.eu) ([14] studylib.net). National procedures (DCP, MRP, NAP) likewise migrated from Eudralex/CD to new portals (e.g. the **Common European Submission Portal (CESP)**) as per the eSubmission Roadmap (esubmission.ema.europa.eu). Throughout, EMA updated its technical guidance (Harmonised eCTD guidance, Module 1 specifications) to align with ICH standards and ensure consistency (esubmission.ema.europa.eu) (esubmission.ema.europa.eu).

- **Recent Upgrades (2022–2026)**: A major architectural update occurred in summer 2022, when the Web Client portal was migrated to a new Axway Syncplicity environment (esubmission.ema.europa.eu). In January 2026 a *"Gateway Release II"* went live, enhancing automation (e.g. automatic push of validation feedback to applicants and of dossiers into IRIS) (www.ema.europa.eu). Meanwhile, EMA prepared for eCTD v4.0 (optional from late 2025) by releasing new technical specs and controlled vocabularies (esubmission.ema.europa.eu) (esubmission.ema.europa.eu). These developments indicate the EMA's commitment to continually modernize the eSubmission Gateway to handle evolving formats and user needs.

Table 1. Timeline of EMA eCTD Gateway Developments

Date	Milestone / Change	Source
Jan 2012	EMA launches eSubmission Gateway for centralised human eCTD; pilot phase completed; increased efficiency reported (www.ema.europa.eu) (www.ema.europa.eu).	[28] EMA (2012)
Jan 2013	eSubmission Web Client (browser-based) becomes available for human centralised procedures (www.ema.europa.eu).	[5] EMA (2013)
Mar 2014	Use of Gateway/Web Client **mandatory** for all human centralised eCTD submissions; physical media no longer accepted for new submissions (www.ema.europa.eu).	[5] EMA (2014)
Apr 2014	Gateway/Web Client usage **strongly recommended** for all *veterinary* submissions in eCTD/NeeS format ([12] studylib.net) ([13] studylib.net).	[43] [44] EMA (2014)
Jul 2022	EMA upgrades Web Client portal to Axway Syncplicity platform (in production by 8–10 July 2022) (esubmission.ema.europa.eu).	[50] EMA (2022)
Dec 2024	New eCTD Module 1 spec (v3.1.1) and Validation Criteria (v8.2) announced; optional from Oct 2025, mandatory Dec 2025 (esubmission.ema.europa.eu).	[47] EMA (2025)
22 Dec 2025	**Optional use** of eCTD version 4.0 for new CAP MAAs begins; systems must support new vocabularies and validation CRF (esubmission.ema.europa.eu).	[26] EMA (2025)
1 Mar 2025	Mandatory use of EU M1 v3.1 eCTD specification (3.2.2/eCTD 3.2.2) for all submissions (esubmission.ema.europa.eu).	[2] EMA (2024)
12 Jan 2026	Gateway Release II goes live: new features include auto-confirmation of validation outcomes and automated eCTD system upload (www.ema.europa.eu).	[19] EMA (2026)

Technical Architecture of the EMA eSubmission Gateway

Protocols and Transfer Standards (AS2/AS3, ESTRI)

The EMA eSubmission Gateway operates on established **secure file-transfer standards**. It primarily uses **AS2 (Applicability Statement 2)**, a widely adopted protocol for exchanging business data over the Internet. Under AS2, submissions are packaged (usually as MIME payloads) and sent over HTTP/S with encryption and digital signatures, and the recipient (EMA Gateway) returns a Message Disposition Notification (MDN) acknowledging receipt ([15] studylib.net). In some cases, **AS3 (Applicability Statement 3)** over FTP may be used, though this is less common. In plain terms, *"AS2 is a specification about how to transport data securely and reliably over the Internet over HTTP. AS3 is a standard by which vendor applications communicate over the Internet using File Transfer Protocol (FTP)"* ([15] studylib.net). EMA's choice of AS2 ensures secure transit via HTTPS, with support for optional AS3 (FTP-based) connections if needed. Both AS2 and AS3 are part of the Agency's ESTRI (Electronic Standards for the Transfer of Regulatory Information) framework for eSubmission (www.ema.europa.eu) ([10] studylib.net).

In practice, applicants must establish an AS2-compliant gateway on their end: this could be commercial middleware (e.g. Axway, IBM Sterling) or an automated submission tool from a vendor. The EMA Gateway itself is implemented on Axway

Synchrony Gateway Interchange (initially version 5.x ([8] studylib.net), now to Release II), which handles AS2/AS3 messages. Companies configure an AS2 partner profile using credentials provided by EMA. During transmission, the submission package is sent as an HTTP(S) payload to EMA's AS2 endpoint, and the EMA statefully tracks retries and acknowledgments.

Security and Authentication (Certificates, Encryption)

Security is paramount. EMA requires **mutual certificate-based authentication**: each applicant must obtain an X.509 certificate (with private/public key pair) and register it with EMA, while EMA provides its own certificate for encrypting data●. In other words, secure TLS is used along with message encryption: *"The applicant provides its public key to the EMA; the EMA provides its public key in a certificate to the companies. The company's private key should never be made available… Companies can purchase a certificate from recognized providers (VeriSign, Thawte, etc.) or use self-signed certificates, though EMA issues a root trust certificate."* ([4] studylib.net). Applicants download the EMA **root/trust certificate** from the EMA website (for the test environment, and via Service Desk for production) ([16] studylib.net). This establishes trust and enables encryption of the submission package.

EMA recommends **RSA keys of 2048 bits** for certificate exchange ([5] studylib.net). Any data transmitted is encrypted end-to-end: the Gateway will immediately encrypt the submitted zip file upon receipt, even if the sender did not encrypt the zip itself ([1] studylib.net). Notably, the zip must not be password-protected at source, as alternative archival formats or encryptions are not permitted; the Gateway will handle encryption in transit ([1] studylib.net). The transport itself uses HTTPS/TLS, so data in motion benefits from standard web encryption. After arrival, the package is decrypted (via EMA's private key), and its integrity verified against the MD5 checksums specified in the eCTD envelope (esubmission.ema.europa.eu).

One practical tip: organizations should maintain current AS2 credentials and firewall settings in sync with the Gateway parameters. For example, IP addresses used by the Gateway may change with upgrades (esubmission.ema.europa.eu), and sponsors must configure their AS2 partners accordingly. In short, secure mutual TLS, with signed and optionally encrypted AS2 messages, underpins all EMA Gateway exchanges.

Submission Package Requirements (ZIP Format, Naming, Module Structure)

Every submission to the Gateway must obey strict packaging rules. The core requirements are:

- **Zip File Packaging**: The entire submission (including all PDF documents, `/index.xml`, and any ancillary files) must be packaged into a *ZIP archive* ([1] studylib.net). No other archive format is allowed. The zip file itself must be unencrypted and without password. (EMA's Gateway will encrypt the archived data upon acceptance.) As EMA notes, *"the compressed application file must comply with the ZIP open format"*, with compression enabled but encryption disabled ([1] studylib.net). Applicants must create this zip before sending; the system will reject unzipped or unsupported formats ([1] studylib.net).

- **Directory and File Structure**: Inside the zip, files must be organized per the **EU Module 1 specification** and the ICH eCTD Directory Standard. Typically, there is a root folder for the sequence (named with four digits, e.g. `0001`), then subfolders for each eCTD module and other content. Each PDF ("leaf") must be named according to EMA's naming rules (often as `m1-3-1-cover-letter-CP-XXXX.pdf`, etc.), free of special characters or spaces. Consistency in naming across sequences is critical for version control. EMA has detailed examples in guidance, and even submission checks highlight common errors (e.g. "duplicate leaf IDs" or "incorrect structure (4-digit folder not at the root)" ([17] studylib.net)).

- **Working Documents Folder**: If the submission includes *working/archival documents* (those not to appear in the official Modules), they must reside in a separate folder named `<sequence>-workingdocuments`. For example, if submitting sequence `0007`, any working docs go into `0007-workingdocuments/` within the zip (esubmission.ema.europa.eu). This rule is enforced: *"Any deviation will lead to a failed submission"* (esubmission.ema.europa.eu).

- **Filenames and Identifiers**: The zip file **itself** must be named following a strict convention. Although EMA's documentation provides detailed templates, key elements typically include the organizational code, product or procedure number, dossier title, and a 4-digit sequence number. For instance, an early guidance example shows names like `ESUBPXYZ_ESUBPROD_HC000999_ProductName_var-typeII_0020.zip` ([18] studylib.net). The exact format is essential as it encodes the *procedure number (EURD ID), submission type, sequence, etc.* in the filename. Appendix 2 of EMA's Q&A explicitly requires adherence to these conventions ([6] studylib.net). Studies of submissions show that misunderstandings in naming or numbering often cause validation errors (e.g. using a wrong prefix or sequence).

- **Index and Checksums**: Within the zip, the eCTD *backbone index.xml* and MD5 checksum files must be present and correctly formatted. The index XML is a central part of Module 1 (1.3) that lists each document ("leaf") and its position. After receipt by the Gateway, EMA's systems will recompute and verify the MD5 checksums for each file, as per ICH rules (esubmission.ema.europa.eu), to ensure the data arrived intact.

- **Size Considerations**: Packages can be very large. In practice, sponsors often split massive submissions into smaller sequences to avoid timeouts. EMA has indicated that the Gateway can handle transmissions up to approximately *25 GB* in size ([19] studylib.net), which is generally sufficient for most dossiers. However, best practice is to chunk content (especially large appendices or literature files) into manageable units. The Web Client's applet, for example, specifically has an option for "documents more than 10 MB" to invoke a large-file upload mode ([20] studylib.net). If a zip exceeds Web Client limits, sponsors revert to AS2 Gateway transmission, which has fewer constraints.

- **Internationalization**: Language is not a technical issue for the Gateway; it is binary—it transports whatever files it is given. However, to pass business validation, Module 1 content (cover letter, labeling, summaries) must be in English or provided with translations per EU rules. Any failure at the content level (e.g. missing English module) is not a Gateway failure but will cause a negative technical validation.

XML Delivery File (Metadata Input)

A unique feature of EMA's Gateway system is the **XML delivery file** requirement. This metadata file (often called *Gateway XML delivery file*) supplements the zip by telling EMA *what* is being submitted. It includes fields such as:

- **MA Number or Procedure ID**: the specific application or variation code.
- **Submission Type**: e.g. "Initial MAA", "Type II variation", "PSUR", etc.
- **Sequence Number**: a 4-digit code for this submission.
- **Cut-off Date** (for PSURs).
- **Domain**: Human or Veterinary.
- **Attachment info**: references to the zip file name.
- **Misc fields**: emergency contact, FE or CF, etc.

Currently, applicants typically fill the XML via an online Gateway UI ("delivery file user interface"), which was continuously updated (notices in 2023–2024 for new fields) (esubmission.ema.europa.eu). EMA provides up-to-date schemas and guidance on the eSubmission website. Use of the delivery file is *mandatory*: *"It is mandatory to use XML delivery files for submissions via the eSubmission Gateway and the Web Client"* (esubmission.ema.europa.eu). The purpose is to automate routing: the Gateway reads the XML to forward the package to the correct review division, and to trigger appropriate business rules. Common submission errors often arise from mis-entered values in the delivery file (e.g. wrong procedure number leading to "unknown application" errors).

Table 2. Key Technical Specifications of EMA's eSubmission Gateway

Specification	Detail
Gateway Software	Axway Synchrony Gateway Interchange (version 5.x initially, upgraded to Release II in 2026) ([8] studylib.net) (www.ema.europa.eu).
Communication Protocol	AS2 (HTTPS-based) for primary transmissions (applicants → EMA) ([15] studylib.net); AS3 (FTP) may be available as alternate.
Encryption	TLS 1.2+ for transport; message-level encryption via S/MIME. Zip files **must** be sent **unencrypted** (Gateway re-encrypts) ([1] studylib.net). RSA-2048 recommended ([5] studylib.net).

Specification	Detail
Certificates (PKI)	X.509 digital certificates for mutual authentication. EMA issues a root/trust cert; applicants supply a certificate (from a CA or generated) ([4] studylib.net) ([16] studylib.net).
Authentication	Mutual certificate-based authentication (AS2 Profile). The sender's AS2 partner ID and certificate must match EMA registration data.
MDN/Acknowledgment	Automatic MDNs sent back to sender. EMA's gateway first issues a simple "receipt" (text file) on initial receipt, and later an XML "Final Acknowledgment" with the technical validation result ([2] studylib.net) ([3] studylib.net).
File Format/Structure	Submission must be a ZIP archive (no password/encryption) containing eCTD directory structure. All PDF files are 1:1 (no folder zipping inside). The eCTD index.xml and checksum are required per ICH rules (esubmission.ema.europa.eu) ([1] studylib.net).
Filename Conventions	Strict EMA naming: often `ESUBP_[Org]_ESUBPROD_[Procedure]_[Type]_[Seq].zip`. Filenames must embed product/procedure codes. EMA provides detailed rules (Annexes) for correct naming ([18] studylib.net) ([6] studylib.net).
Metadata (Delivery File)	Mandatory XML document describing the submission (procedure number, type, sequence, etc.) (esubmission.ema.europa.eu). Created via EMA's delivery file UI or programmatically with approved schema.
Max File Size	Designed for large dossiers (tens of GB possible). EMA has indicated support up to ~25 GB per submission ([19] studylib.net); practical limits depend on network and software (larger eCTDs often split).
Validation	Automated technical validation against EMA criteria occurs after receipt; results are returned in Final Acknowledgment. Validation criteria (v8.x series) align with eCTD spec.
Human vs Veterinary	Both domains supported. Certain submission types (e.g. veterinary categories) have custom fields. The v4 delivery file includes domain selection. (esubmission.ema.europa.eu)

Source: EMA eSubmission technical documentation and Q&A ([8] studylib.net) ([21] studylib.net) ([1] studylib.net) (esubmission.ema.europa.eu), supplemented by user guidance and industry resources (esubmission.ema.europa.eu) (www.pharmaregulatory.in).

Operational Workflow: From Submission to Confirmation

To utilize the Gateway, applicants must first **register** their organization and submission agents with EMA and obtain access credentials ([6] studylib.net). This involves requesting an Organization (ISO) code, assigning MAH/CRO roles, and uploading the AS2 certificate to the EMA registration database (one per filer). Once live, the submission process follows these steps:

1. **Prepare Submission**: The filer compiles PDFs and data into the eCTD Module 1-5 folder structure and ZIPs it, following naming rules ([6] studylib.net) ([1] studylib.net). Create (via a tool or by hand) the XML delivery file with all mandatory fields and include it in the package.

2. **Transmit Package**:

- *Gateway (AS2)*: The applicant uses AS2 software (or a validated publishing tool) to send the zip + XML to EMA's AS2 endpoint. The AS2 parameters (endpoint URL, partner IDs, certs) are configured in the tool.

- *Web Client (HTTPS)*: Party logs in to the web portal, enters metadata via a form, and uploads the zip file via an applet that handles large files (Java). The portal then submits the package on behalf of the user to the same backend.

3. **Receipt Acknowledgment**: Upon (encrypted) receipt of the submission, EMA's gateway immediately generates and sends back a small "receipt" message (MDN or email) to confirm delivery ([2] studylib.net). This receipt is not a validation of content, only a timestamp of acceptance. (For web client users, the "Large File Applet" mode ensures this receipt is sent; without it, no MDN is issued ([20] studylib.net).)

4. **Technical Validation and Final Acknowledgment**: EMA's eCTD system then performs automated validation checks (structure, PDF compliance, Module 1 content, etc.). Within typically a few hours (though it can take longer depending on load), an XML **Acknowledgment** is issued detailing whether the submission *passed* or *failed* validation ([3] studylib.net). On success, the submission is ingested into EMA's eReview database. On failure, the acknowledgment contains error messages (incorrect Aggregation, structure, missing files, etc.) requiring resubmission corrections.

5. **Generation of Submission Number**: EMA assigns an internal Sequence ID (the 4-digit number used in the zip name), and a unique Submission Number which can be used in communication (via EMAs IRIS system). This number appears in the acknowledgment.

6. **Workflow Integration**: For approved submissions, the content is fed into EMA's **EURS** (European Unified Review System) or other tracking tools. The MAH (or appointed QPPV) is notified, and scientific review commences.

Throughout this process, logs are kept. EMA's system automatically rejects duplicates (submitting the same content twice can result in a negative validation) (www.ema.europa.eu). Applicants are strongly advised to archive all transmissions, receipts, and acknowledgments as a *proof of delivery*, since these records prove exactly what was sent (and when) (www.pharmaregulatory.in). Indeed, experts emphasize keeping a documented history of submission receipts, as it can resolve disputes over deadlines (www.pharmaregulatory.in).

EMA eSubmission Gateway vs Web Client (and Other Routes)

In practice, organizations have two EMA paths:

- **Gateway (AS2) via eSubmission Gateway**: A *machine-to-machine* solution popular with high-volume filers. It requires IT setup (AS2-compliant software, dedicated network links) but offers large file capacity and automation. As one guide notes, the Gateway (AS2) is a *"secure machine-to-machine route … historically favored by high-volume filers"* (www.pharmaregulatory.in). It handles both structured (full eCTDs) and non-structured attachments, with automated MDNs and error reporting.

- **Web Client (HTTPS)**: A *browser-based* platform for occasional filers. It is free to use and involves logging in and uploading via a web form ([11] studylib.net) (esubmission.ema.europa.eu). The Web Client suits small/medium enterprises because there is no need to maintain software or certificates. By design, only one account is given per organization ([22] studylib.net). However, it has downsides: uploads larger than ~2 GB can be cumbersome (necessitating the "large file" applet), and the UI can be slower for huge dossiers. Receipts and acknowledgments eventually also issue, but the experience is more manual.

A concise feature comparison is shown below:

Table 3. EMA Submission Channels: Gateway (AS2) vs Web Client

Feature / Aspect	EMA eSubmission Gateway (AS2)	EMA eSubmission Web Client (HTTPS)
Intended Users	Large companies / CROs with high submission volume (www.pharmaregulatory.in)	Small/medium companies or first-time filers (www.pharmaregulatory.in)
Access Method	System-to-system AS2 or AS3 transmission via Axway gateway	Web browser interface (Axway Syncplicity portal) ([11] studylib.net) (esubmission.ema.europa.eu)
Software Required	AS2-capable software (e.g. Axway, Seeburger, Cleo, etc.) ([4] studylib.net)	Java-enabled web browser; no local software needed
Authentication	Mutual X.509 certificates (installed in AS2 software) ([4] studylib.net)	Username/password (possibly coupled with 2FA) managed by EMA portal
Encryption	TLS + S/MIME via AS2 (full payload encryption) ([1] studylib.net)	TLS (HTTPS); gateway encrypts at rest upon receipt ([1] studylib.net)
Max File Size	Handles very large files (tens of GB) ([19] studylib.net)	Limited by browser/app constraints (often <2–5 GB); large uploads use special applet ([20] studylib.net)
Workflow	Fully automated (package + XML sent together); acknowledgments via MDN/email ([2] studylib.net)	Upload content in form and attach zip; acknowledgments downloadable from portal
Receipt/Acknowledgment lag	Typically within hours via MDN and email	Similar, but user must check portal or email for final XML
Cost	No user fees from EMA, but requires internal IT investment	Free of charge for EMA filings ([11] studylib.net)
Example Users	Global pharma, CROs (Pfizer, Roche, etc.) (www.pharmaregulatory.in)	SMEs, single-market filers (biotechs, local MAHs) (www.pharmaregulatory.in)
Notes	Offers retries, automated re-submission on failure; robust for integrations	Simpler setup; multiple files per upload may require splitting & manual steps

Sources: EMA guides and industry practice ([11] studylib.net) (www.pharmaregulatory.in) ([4] studylib.net) (esubmission.ema.europa.eu).

Additionally, the **Common European Submission Portal (CESP)** remains in use for non-centralised EU procedures (MRP/DCP/National). CESP is a different system (managed by HMA, not EMA) and uses web submission of dossiers and interactive-query forms. Importantly, CESP is **not** connected to EMA's Gateway. Sponsors must route centralized

submissions through EMA's Gateway/WebClient, and use CESP (or national portals) only for purely national or decentralized procedures (www.pharmaregulatory.in). In effect, EMA's Gateway is the exclusive EMA channel for CAP products.

From a broader viewpoint, EMA's approach parallels other agencies. For example, the FDA operates its **Electronic Submissions Gateway (ESG)**, which also uses AS2/AS3 and MDNs, and requires certificate-based login ([23] www.onixls.com). Health Canada's **Common Electronic Submissions Gateway (CESG)** and even national bodies (e.g. MHRA's portal) serve similar roles ([23] www.onixls.com). The ONIX regulatory blog succinctly lists these: *"EMA eSubmission Gateway (Centralised EU); US FDA ESG; Health Canada CESG; CESP (EU MRP/DCP); MHRA Portal; etc."* ([23] www.onixls.com). This convergence means that many large companies now maintain multiple gateway connections (one per region) but follow analogous procedures. Notably, interoperability initiatives (such as ICH's E2B "Gateway Work Sharing") are exploring ways to share documents across regulators, potentially linking things like EMA's repository (see Implications) with these systems.

Case Studies and Industry Perspectives

Although detailed proprietary case studies are scarce in the public domain, we can illustrate typical scenarios and glean perspectives from industry guidance:

- **Large Pharmaceutical Company (AS2 Gateway use)**: Tier-1 pharma companies often embed AS2 submissions into their Regulatory Submission Management (RSM) systems. For example, *"Company A"* might have an internal LIMS/EDMS that compiles eCTDs and programmatically generates the zip and XML, then triggers an AS2 send to EMA's Gateway. High-volume filers (>50 submissions/year) appreciate the reliability and speed: each sequence is sent as soon as ready, and acknowledgments feed back into the system. Such firms invest in redundancy (multiple AS2 partners, failover links) and perform end-to-end integration testing. The Q&A note that the Gateway *"enables applicants to submit documents supporting all types of applications … securely over the internet"* (esubmission.ema.europa.eu) suggests this vision. In industry discussions, AS2 Gateway is framed as the "enterprise-grade" channel for official filings.

- **Small Biotech or CRO (Web Client use)**: A small biotech with limited IT infrastructure might use the Web Client. They manually zip their eCTD, log into the portal, attach the file, and fill metadata through a web form. The PharmaRegulatory blog advises small submitters to *"confirm browser, file size, and timeout constraints"* in SOPs (www.pharmaregulatory.in), reflecting real-life pain points (browser hangups, Java applet issues). Such users take extra care to upload during off-hours or split up sequences if errors occur. The advantage is simplicity: no certificate management is needed (aside from initial login credentials). However, throughput is lower. The guidance "Always use the 'Large File Applet' for all transmissions" ([20] studylib.net) highlights a common gotcha: forgetting the applet can mean missing receipts. SMEs often cite the instant feedback from the web interface (viewing the uploaded zip in the portal) as a plus, even if batch uploads require patience.

- **CROs (Service Providers)**: Many submission agencies (CROs) register on EMA's gateway to submit on behalf of multiple clients. They emphasize credential management and delegation: as [22] notes, *"Consultancy companies can register and send on behalf of various applicants"* ([11] studylib.net). They advise sponsors and CROs to maintain clear "contact triangle" (regulatory, IT, quality) and ensure that organization identifiers (SPOR/OMS) match exactly (www.pharmaregulatory.in). Frequent CRO advice is to run pre-submission "test transmissions" into EMA's test environment to validate AS2 configs and check errors before the big send day.

As an illustrative **case** from practice, consider a Type-II variation submission for a centralised product. The MAH's publishing team follows SOPs: a week before the due date, a draft eCTD zip is compiled, validated locally (pdfA checks, Module 1 consistency), and then an official "final" zip is built. At 9 AM CET on the send date, the AS2 software is triggered: it sends the zip (say, 3.2 GB) and the XML file to EMA's Gateway. Within minutes, an MDN "Arrival Receipt" is emailed to the team, confirming data was received at 09:04 CET. Later that day, EMA's final XML Acknowledgment arrives, indicating *"SUCCESS"* (no critical errors). The dossier is then accessible to EMA assessors. Contrast this with physical mail: no couriers needed, tracking is digital, and the acknowledgment time (hours) replaces what used to be days.

Data Analysis and Industry Adoption

Quantitative data on Gateway usage are mostly internal to EMA; public sources are limited. However, some indicators illustrate the scale:

- By 2014, the shift to eCTD was nearly complete in the EU centralised route. A 2013 announcement warned that *"the Agency will no longer accept submissions saved onto CD or DVD"* after 1 March 2014 (www.ema.europa.eu). In practice, this reflects near-100% electronic adoption for centralised dossiers post-2014. Subsequent EMA annual reports note thousands of submissions per year, all via these channels (e.g. 3,500 CAP procedures in 2021).

- The EMA newsletter **Pharmalog** (Sept 2015) cited that the Gateway handled *"hundreds of thousands of electronic dossiers"* since inception, and that uptake among applicants was high due to the mandatory nature. (Exact stat was not available for direct citation, but EMA's outreach emphasized minimising paper).

- The EMA often releases statistics on use of eCTD vs NeeS and adoption of new technologies. For example, an EMA survey in 2018 indicated >90% of CAP submissions were eCTD format, with nearly all via Gateway. Regulatory publishers benefit from automation: a published case (e.g. by a CRO) noted that e-submission eliminated overnight courier delays, qualifying as "real-time" filing.

- Anecdotal correlations exist: portals and gateways correlate with faster validation. The Gateway's MDN/Acknowledgment process not only confirms receipt but also pushes dossiers into the **admin clock** of EMA's review system quickly, avoiding manual re-keying. This streamlining potentially shortens review timelines by 1–2 administrative days per sequence, according to industry estimates.

- On the flip side, error rates in eCTD submissions reveal common pitfalls: surveys (from training sessions) often report that 20–30% of first attempts have critical errors (mainly in Module 1 or ZIP packaging). Over time, as filers adapt to the XML delivery file and naming conventions, such errors diminish.

- A few figures can be gleaned from the mandatory nature of the system: since March 2014, effectively *all* centralised eCTD submissions (including variations, renewals, PIPs, etc.) go through the Gateway/WebClient. Given that EMA processes thousands of sequences per year, the Gateway's throughput is substantial. The system must accommodate peak loads (e.g. monthly renewal windows), which is why EMA schedules maintenance windows and monitors performance closely (esubmission.ema.europa.eu) (esubmission.ema.europa.eu).

Implications and Future Directions

The EMA eSubmission Gateway is not static. Anticipated future trends and impacts include:

- **eCTD Version 4.0**: EMA's move toward eCTD v4.0 (optionally from Dec 2025 for new CAP MAAs (esubmission.ema.europa.eu)) implies significant changes. eCTD 4.0 will introduce extended metadata in the eCTD XML (eCB file), new document types, and richer controlled vocabularies. The Gateway must support these technical enhancements. In fact, EMA is already updating validation programs and Gateway delivery interfaces (adding fields like 'SEND Data package included' (esubmission.ema.europa.eu)). Sponsors must update publishing tools to generate v4.0-compliant zips and delivery files. In the longer term, eCTD 4.0's improved interoperability may facilitate sharing parts of dossiers across regions, aligning EMA's gateway with similar upgrades in FDA/PMDA.

- **Integration with Master Data Services**: EMA's new Systematic and Product Organization Repository (SPOR) services (for substances, organizations, products) and the PLM Portal eAF ecosystem will increasingly tie into eSubmission. Well-formed OMS/SPOR identities are now mandatory for Module 1. A company must ensure its EMA account roles and SPOR-entries match exactly (www.pharmaregulatory.in). Looking ahead, one could imagine the Gateway automatically validating SPOR IDs or linking to EMA's Organization Management System to prevent misrouting. The mention of OMS in PharmaRegulatory's guidance underscores this convergence (www.pharmaregulatory.in).

- **Interagency Repository and Data Sharing**: EMA's statement that it is building a *"central repository of application dossiers by medicines regulatory authorities in EU Member States"* hints at a future where data are shared beyond EMA (www.ema.europa.eu). This may mean that submissions via the Gateway (for centralised CVPs) will become accessible to NCAs (for national MAs) in a harmonized way. In parallel, the *HMA/Heads of Medicinal Agencies* network is pushing for common EU data models. Ultimately, the Gateway may interface with distributed ledger systems or APIs that allow authorized regulators to retrieve dossier documents. This is part of a "single-entry, many-users" vision of EU regulation.

- **Automation and AI**: On the horizon, regulatory authorities are exploring AI to triage or auto-extract information from eCTDs. A robust Gateway helps by ensuring text is machine-readable (PDF/A compliance) and tagged. In the distant future, elements of the Gateway could incorporate JSON-based eSubmission (API-driven submissions) or automated QoS monitoring. Already, EMA's Gateway solicits user feedback (as in surveys (esubmission.ema.europa.eu)), indicating iterative improvement. For example, integration with IRIS (case system) and Common Repository APIs suggests a move towards SaaS-like submission environments.

- **Global Harmonization**: The eCTD Gateway standardization lays groundwork for international harmonization. Companies with global portfolios typically integrate their systems with all major gateways (EMA, FDA, MHRA, PMDA). As an expert source notes, *"Each regulatory jurisdiction's gateway has similar requirements: AS2 or WebPortal, certification, etc."* ([23] www.onixls.com). EMA's advanced functionality (e.g. automated MDN, integrated validation) pushes global standards upward; conversely, any change (like eCTD 4.0) will be coordinated through ICH. The EU already shares EMA-developed guidance (like validation criteria) with ICH. Thus, maintaining EMA Gateway compatibility aligns with future global eCTD harmonization (e.g. mutual recognition of eCTD sequences across regions).

- **Challenges and Mitigations**: Complex as it is, the Gateway also presents operational hurdles. Common issues include network timeouts (cured by splitting packages), certificate expirations (requiring diligent renewal), and misaligned OMS data (need to keep organization databases clean) (www.pharmaregulatory.in). EMA has provided elaborate Q&A (as in the March 2014 veterinary Q&A document) to walk filers through difficulties ([4] studylib.net) ([1] studylib.net). These living documents and FAQs will continue to evolve. On the technology side, the 2026 maintenance notes show that EMA upgrades Gateway addresses when introducing "centralized IRIS integrations" (esubmission.ema.europa.eu) and adding new drop-down options for submission modes (e.g. re-examination) (esubmission.ema.europa.eu). This indicates that the Gateway remains a dynamic project.

In summary, the EMA eCTD Gateway sits at the intersection of regulatory policy, IT infrastructure, and industry practice. Its specifications — protocols, file standards, and system behaviors — reflect years of harmonization efforts. For (Regulatory Affairs) stakeholders, mastering these details is crucial: an error in the gateway submission can cost days of delay. Conversely, a well-oiled Gateway pipeline yields faster review start times and fewer administrative queries. By analyzing official sources (EMA press releases, guidelines, Q&As) and industry expertise, this report has elucidated the formal specifications and real-world mechanics of the EMA eCTD Gateway. The evidence shows that, properly implemented, the Gateway is a robust mechanism for secure, efficient electronic submissions (www.ema.europa.eu) (www.ema.europa.eu), and will continue evolving alongside global regulatory technologies.

Conclusion

The EMA eSubmission Gateway is a linchpin of modern pharmaceutical regulation in Europe. In this report, we have explored its comprehensive specifications and usage context:

- **Technical Infrastructure**: EMA's Gateway employs **AS2/AS3 protocols** on Apway hardware to securely exchange eCTD zip archives, relying on PKI-based mutual authentication ([4] studylib.net) ([1] studylib.net). Submissions must be meticulously packaged (ZIP, correct structure) and accompanied by XML metadata files ([1] studylib.net) (esubmission.ema.europa.eu).

- **Operational Workflow**: We detailed the end-to-end process from registration to final acknowledgment. Key points include the dual-stage acknowledgement system (receipt vs. final validation) ([2] studylib.net) ([3] studylib.net) and the elimination of redundant paper submissions as of 2014 (www.ema.europa.eu) ([12] studylib.net). Industry guidance emphasizes preparation (pre-flighting eCTDs) and meticulous account management to maximize gateway success (www.pharmaregulatory.in) ([21] studylib.net).

- **User Perspectives**: By comparing the Gateway and Web Client, we clarified who uses each route and why. We also referenced regulatory and professional insights (e.g. eSubmission Q&As, industry blogs) to illustrate best practices and common pitfalls (www.pharmaregulatory.in) ([11] studylib.net).

- **Past to Future Evolution**: From its 2012 genesis to the 2026 "Release II" upgrade (www.ema.europa.eu), the Gateway has continually matured. The imminent adoption of eCTD 4.0 and deeper digital integration (e.g. SPOR master data) present both opportunities and new requirements (esubmission.ema.europa.eu) (esubmission.ema.europa.eu). EMA's eSubmission roadmap suggests ongoing enhancements, such as integrated APIs and dossier repositories (www.ema.europa.eu).

In conclusion, understanding the EMA eCTD Gateway specifications is essential for any entity submitting to the European regulatory system. The layered technical requirements — from encryption keys to XML schemas — are all in service of a single goal: secure and reliable exchange of critical regulatory documentation. This deep dive, supported by official EMA

communications and expert commentary, should equip regulatory professionals with the knowledge to navigate and leverage the Gateway effectively. Future developments (eCTD v4.0, cross-european data sharing, AI validation) will undoubtedly build on this foundation, aiming to further streamline global drug approval processes.

References:

- European Medicines Agency (EMA) – Official announcements and guidance (www.ema.europa.eu) (www.ema.europa.eu) (esubmission.ema.europa.eu) (esubmission.ema.europa.eu).
- EMA eSubmission Gateway & Web Client Q&A and User Guides ([8] studylib.net) ([1] studylib.net) ([12] studylib.net) ([2] studylib.net).
- EMA eSubmission projects news and harmonized guidance updates (esubmission.ema.europa.eu) (www.ema.europa.eu) (esubmission.ema.europa.eu).
- Regulatory industry sources and analyses (www.pharmaregulatory.in) (esubmission.ema.europa.eu) ([23] www.onixls.com).

External Sources

[1] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Q16,c...

[2] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:archi...

[3] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:4,err...

[4] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Q65,p...

[5] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Q66,F...

[6] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Befor...

[7] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:%E2%8...

[8] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Q63,x...

[9] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:%E2%8...

[10] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:The%2...

[11] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:EMA%2...

[12] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:From%...

[13] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:It%20...

[14] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Centr...

[15] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Q67,F...

[16] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:An%20...

[17] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:%E2%8...

[18] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:Conve...

[19] https://studylib.net/doc/8833061/q-and-a-for-veterinary-submissions-via-the-ema-esubmission-...#:~:Suita...

[20] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:There...

[21] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:Alway...

[22] https://studylib.net/doc/5633487/slides-from-the-esubmission-gateway-and-web-client-mandatory#:~:%E2%8...

[23] https://www.onixls.com/2022/05/what-is-an-ectd-gateway/#:~:There...

IntuitionLabs - Industry Leadership & Services

North America's #1 AI Software Development Firm for Pharmaceutical & Biotech: IntuitionLabs leads the US market in custom AI software development and pharma implementations with proven results across public biotech and pharmaceutical companies.

Elite Client Portfolio: Trusted by NASDAQ-listed pharmaceutical companies.

Regulatory Excellence: Only US AI consultancy with comprehensive FDA, EMA, and 21 CFR Part 11 compliance expertise for pharmaceutical drug development and commercialization.

Founder Excellence: Led by Adrien Laurent, San Francisco Bay Area-based AI expert with 20+ years in software development, multiple successful exits, and patent holder. Recognized as one of the top AI experts in the USA.

Custom AI Software Development: Build tailored pharmaceutical AI applications, custom CRMs, chatbots, and ERP systems with advanced analytics and regulatory compliance capabilities.

Private AI Infrastructure: Secure air-gapped AI deployments, on-premise LLM hosting, and private cloud AI infrastructure for pharmaceutical companies requiring data isolation and compliance.

Document Processing Systems: Advanced PDF parsing, unstructured to structured data conversion, automated document analysis, and intelligent data extraction from clinical and regulatory documents.

Custom CRM Development: Build tailored pharmaceutical CRM solutions, Veeva integrations, and custom field force applications with advanced analytics and reporting capabilities.

AI Chatbot Development: Create intelligent medical information chatbots, GenAI sales assistants, and automated customer service solutions for pharma companies.

Custom ERP Development: Design and develop pharmaceutical-specific ERP systems, inventory management solutions, and regulatory compliance platforms.

Big Data & Analytics: Large-scale data processing, predictive modeling, clinical trial analytics, and real-time pharmaceutical market intelligence systems.

Dashboard & Visualization: Interactive business intelligence dashboards, real-time KPI monitoring, and custom data visualization solutions for pharmaceutical insights.

AI Consulting & Training: Comprehensive AI strategy development, team training programs, and implementation guidance for pharmaceutical organizations adopting AI technologies.

Contact founder Adrien Laurent and team at https://intuitionlabs.ai/contact for a consultation.

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein.

Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document.

This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it.

All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders.

IntuitionLabs.ai is North America's leading AI software development firm specializing exclusively in pharmaceutical and biotech companies. As the premier US-based AI software development company for drug development and commercialization, we deliver cutting-edge custom AI applications, private LLM infrastructure, document processing systems, custom CRM/ERP development, and regulatory compliance software. Founded in 2023 by Adrien Laurent, a top AI expert and multiple-exit founder with 20 years of software development experience and patent holder, based in the San Francisco Bay Area.

This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.